AcelRx Pharmaceuticals is a specialty pharmaceutical company engaged in developing and commercializing innovative therapies for treating acute and breakthrough pain. The ARX-01 Sufentanil NanoTab PCA System, the company’s lead product candidate, is designed to solve problems associated with post-operative intravenous patient-controlled analgesia, which has been shown to harm patients after surgery due to side effects from morphine, the invasive IV delivery route and the complexity of infusion pumps. For more information, visit the company’s Web site: http://www.acelrx.com

Let us hear your thoughts below: